The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV)
Open accessAbstract
Purpose We sought to characterize the natural history of vascular Ehlers-Danlos syndrome in individuals with heterozygous COL3A1 mutations.Methods We reviewed clinical records for details of vascular, bowel, and organ complications in 1,231 individuals (630 index cases and 601 relatives).Results Missense and splice-site mutations accounted for more than 90% of the 572 alterations that we had identified in COL3A1. Median survival was 51 years but was influenced by gender (lower in men) and by the type of mutation.Conclusion Although vascular Ehlers-Danlos syndrome appears to be genetically homogeneous, allelic heterogeneity is marked, and the natural history varies with gender and type of mutation in COL3A1. These findings indicate that when counseling families, confirmation of the presence of a COL3A1 mutation and its nature can help evaluate the risks of complications. These data are also important ingredients in both the selection and allocation of individuals to appropriate arms in clinical trials to assess the effects of interventions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The majority of disease-causing variants in COL3A1 are glycine substitutions and in-frame splice mutations in the triple helix domain”
In the citing paper
“through a dominant negative effect are associated with the severe clinical spectrum potentially lethal of vEDS, characterized by fragility of soft connective tissues with arterial and organ ruptures.”
In the citing paper
“This type of mutations produces a dominant negative effect on the protein, thereby inhibiting extracellular accumulation of mature COLLIII.”
In the citing paper
“Substitutions of bulky residues (Arg, Asp, Glu, Val) for glycine residues in the triple helical domain are usually less severe than splice site mutations, but more consequential than substitutions by smaller residues (Ala, Ser, Cys).”
In the citing paper
“the nature of the specific COL3A1 mutation influences life expectancy.”
In the citing paper
“Splice site mutations that lead to exon skipping have the lowest median survival.”
In the citing paper
“Heterozygosity for COL3A1 null alleles typically produces a milder clinical phenotype with a significant delayed onset of complications [4, 9–12].”
In the citing paper
“COL3A1 missense mutations altering the glycine codons together with in-frame splice mutations in the triple helical domain account for the majority of disease-causing variants and lead to misfolding of COLLIII in the endoplasmic reticulum (ER) and retention of seven eighths of misfolded procollagen trimers in the cell with consequent enlargement of ER vesicles [8–10].”
In the citing paper
“Besides, the present patients exhibited a full-blown expression of the disease with several major arterial events, in line with the limited genotype-phenotype correlation that associates this type of structural mutations with a more severe clinical phenotype [4,9–12].”
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type
Pepin, M., Schwarze, U., Superti-Furga, A., & Byers, P. H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421001 · Cited by 1,344
Self-citationMarini, J. C., Forlino, A., Cabral, W. A., Barnes, A. M., Antonio, J. D. S., Milgrom, S. A., Hyland, J. C., Körkkö, J., Prockop, D. J., Paepe, A. D., et al. (2006) · Human Mutation · doi:10.1002/humu.20429 · Cited by 773
Self-citationConnective tissue and its heritable disorders : molecular, genetic, and medical aspects
Royce, P. M., & Steinmann, B. U. (1993) · Cited by 440
LANNE, R. D. (1952) · Acta Clinica Belgica · doi:10.1080/17843286.1952.11717220 · Cited by 212
Superti‐Furga, A., Gugler, E., GITZELMANN, R., & Steinmann, B. U. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68776-9 · Cited by 198
Connective tissue and its heritable disorders. Molecular, genetic and medical aspects
Olavesen, A. H. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80460-c · Cited by 198
Cerebrovascular complications in Ehlers‐Danlos syndrome type IV
North, K. N., Whiteman, D. A. H., Pepin, M. G., & Byers, P. H. (1995) · Annals of Neurology · doi:10.1002/ana.410380620 · Cited by 186
Self-citationPregnancy-related deaths and complications in women with vascular Ehlers–Danlos syndrome
Murray, M. L., Pepin, M. G., Peterson, S., & Byers, P. H. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.53 · Cited by 183
Self-citationLeistritz, D. F., Pepin, M. G., Schwarze, U., & Byers, P. H. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182180c89 · Cited by 141
Self-citationTreatment of Vascular Ehlers-Danlos Syndrome
Bergqvist, D., Björck, M., & Wanhainen, A. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31829c7a59 · Cited by 113
Persikov, A. V., Pillitteri, R. J., Amin, P., Schwarze, U., Byers, P. H., & Brodsky, B. (2004) · Human Mutation · doi:10.1002/humu.20091 · Cited by 107
Self-citationEhlers–Danlos Syndrome Type IV
Pinto, Y. M., Pals, G., Zijlstra, J. G., & Tulleken, J. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430513 · Cited by 32
Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997
Beighton, P., Paepe, A. D., Steinmann, B., Tsipouras, P., & Wenstrup, R. J. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980428)77:1
Cited by
Sorted by citations
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixidó‐Turà, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., Backer, J. F. A. D., Déglise, S., Corte, A. D., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 1,313
Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases
Kuivaniemi, H., & Tromp, G. (2019) · Gene · doi:10.1016/j.gene.2019.05.003 · Cited by 444
Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome
Byers, P. H., Belmont, J., Black, J., De Backer, J., Frank, M., Jeunemaitre, X., Johnson, D., Pepin, M., Robert, L., Sanders, L., et al. (2017) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31553 · Cited by 381
Self-citation2025 ESC Guidelines for the management of cardiovascular disease and pregnancy
Backer, J. F. A. D., Haugaa, K. H., Hasselberg, N. E., de Hosson, M., Brida, M., Castelletti, S., Cauldwell, M., Cerbai, E., Crotti, L., de Groot, N. M. S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf193 · Cited by 380
Malfait, F., Castori, M., Francomano, C. A., Giunta, C., Kosho, T., & Byers, P. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0194-9 · Cited by 346
Self-citation
Metadata
- Authors
- Pepin, M. G., Schwarze, U., Rice, K. M., Liu, M., Leistritz, & Byers, P. H.
- Affiliations
- University of Washington (US)
- Corresponding author
- Pepin, Melanie G.
- Venue
- Genetics in Medicine
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 16
- Issue
- 12
- Pages
- 881-888
- ISSN
- 1098-3600 (ISSN-L)
- OpenAlex
- W2030732677
- Cited by
- 313
- References
- 16
- Citations by year
- 2026: 29 · 2025: 30 · 2024: 35 · 2023: 29 · 2022: 37 · 2021: 27 · 2020: 24 · 2019: 30 · 2018: 26 · 2017: 18 · 2016: 16 · 2015: 10 · 2014: 2
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Genetics in Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- vascular Ehlers-Danlos syndrome, COL3A1 mutation, missense mutations, splice site mutation, natural history (disease), survival, allelic heterogeneity, gender differences, bowel complications, vascular complications, family counseling, clinical trial selection
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Alleles, Child, DNA Mutational Analysis, Ehlers-Danlos Syndrome, Female, Humans, Male, Middle Aged, Mutation, RNA Splicing, Genetic Variation, Treatment Outcome, Mutation, Missense, Collagen Type III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
